The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose escalation study of TG02 in patients with advanced hematologic malignancies.
Gail J. Roboz
No relevant relationships to disclose
Hanna Jean Khoury
No relevant relationships to disclose
Jamile M. Shammo
No relevant relationships to disclose
Mary Syto
Stock Ownership - Tragara Pharmaceuticals
Francis Burrows
Stock Ownership - Tragara Pharmaceuticals
Sara L. Zaknoen
Stock Ownership - Tragara Pharmaceuticals
Elias Jabbour
No relevant relationships to disclose